Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q2- Text added to 2022 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
accrued, aforementioned, Balstilimab, Belgium, biologic, center, certainty, complex, confidentiality, credible, Denmark, derecognized, detriment, devote, dossier, effort, encoding, engineered, extinguishment, face, faculty, Finland, frequency, genetically, guarantor, hand, inspected, insufficient, integrity, iv, labeling, local, monitoring, percent, recall, refinanced, refinancing, regular, risky, SE, standing, subscription, substandard, suspension, Sweden, Switzerland, utilize, utilized, Valneva, withdrawal
Valuein 2022 Q2 filing- Value in 2022 Q3 filing
Original filings
Filing view